917358-65-7

Basic information

• Product Name: N-Methylpiperazine--d8
• Synonyms: N-Methylpiperazine--d8;1-methylpiperazine-2,2,3,3,5,5,6,6-d8;1-methyl-(2,2,3,3,5,5,6,6-d8)piperazine Dichloride
• CAS NO: 917358-65-7
• Molecular Formula: C₅H₁₂N₂
• Molecular Weight: 108.211474224
• Mol File: 917358-65-7.mol

Chemical Properties

• Appearance: /
• Density: 0.974 g/mL at 25 °C
• CAS DataBase Reference: N-Methylpiperazine--d8(CAS DataBase Reference)
• NIST Chemistry Reference: N-Methylpiperazine--d8(917358-65-7)
• EPA Substance Registry System: N-Methylpiperazine--d8(917358-65-7)

Safety Data

• Hazard Codes: T
• Statements: 10-21-23-34
• Safety Statements: 16-26-36/37/39-45
• Hazardous Substances Data: 917358-65-7(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
N-Methylpiperazine--d8 is used as a key intermediate in the preparation of 2-(4-Methyl-1-piperazinylmethyl)acrylophenone (MPMAP), an antimicrotubular drug. It aids in the development of this drug, which has potential applications in treating various diseases by disrupting microtubule dynamics in cells.
Used in COVID-19 Research:
N-Methylpiperazine--d8 is used as a COVID-19-related research product, contributing to the ongoing efforts to understand and combat the virus. Its involvement in research may lead to the discovery of new treatments or therapeutic approaches against COVID-19.
Used in Inflammatory Disorders Treatment:
N-Methylpiperazine--d8 is used in the preparation of Imidazopyridine compounds, which have potential applications in the treatment of inflammatory disorders. These compounds may help in managing inflammation and related symptoms by targeting specific pathways involved in the inflammatory response.

Upstream product

• 1189436-83-6 1-(tert-butoxycarbonyl)-4-methyl-(2,2,3,3,5,5,6,6-d₈)piperazine 
• 1126621-86-0 tert-butyl (2,2,3,3,5,5,6,6-(²H₈))piperazine-1-carboxylate 

Downstream Products

• 1092942-82-9 [D₈]-imatinib 

Relevant articles and documents

DEUTERIUM-MODIFIED BRIGATINIB DERIVATIVES, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, AND USE THEREOF

The present invention relates to the field of pharmaceutical chemistry, and relates to a deuterium-modified Brigatinib derivative, preparation method thereof, pharmaceutical composition containing the same and the uses of the deuterium-modified Brigatinib derivative and the pharmaceutical composition thereof in preparing a medicament for treating the disease mediated by anaplastic lymphoma kinase. The deuterium-modified Brigatinib derivative of the present invention has an excellent inhibitory activity on anaplastic lymphoma kinase and has better pharmacodynamic or pharmacokinetic properties relative to Brigatinib.

KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE

Disclosed herein are new compounds and compositions and their application as pharmaceuticals for the treatment of diseases. Methods of inhibition of KDM1A, methods of increasing gamma globin gene expression, and methods to induce differentiation of cancer cells in a human or animal subject are also provided for the treatment of diseases such as acute myelogenous leukemia.